Cardiac Biomarker Testing Market to reach USD 10.21 billion by 2032 with a growing CAGR of 9.47%
The Cardiac Biomarker Testing Market is witnessing substantial growth, driven by the rising global prevalence of cardiovascular diseases, advancements in diagnostic technologies, and growing public awareness regarding heart health. Cardiovascular diseases remain the leading cause of death globally, responsible for an estimated 17.9 million deaths annually, according to the World Health Organization. This has underscored the need for accurate, accessible diagnostic tools to detect heart conditions early, enabling timely intervention. Biomarker tests, such as troponins, B-type natriuretic peptides, and high-sensitivity C-reactive protein, have become invaluable for diagnosing heart attacks, heart failure, and other CVDs, making them essential in clinical practice worldwide.